- Home
- USGO vs ELTX Comparison
USGO vs ELTX Comparison
Compare USGO & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USGO
- ELTX
- Stock Information
- Founded
- USGO 2015
- ELTX 2011
- Country
- USGO United States
- ELTX United States
- Employees
- USGO N/A
- ELTX N/A
- Industry
- USGO Precious Metals
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- USGO Basic Materials
- ELTX Health Care
- Exchange
- USGO Nasdaq
- ELTX Nasdaq
- Market Cap
- USGO 117.3M
- ELTX 121.7M
- IPO Year
- USGO 2023
- ELTX N/A
- Fundamental
- Price
- USGO $8.25
- ELTX $7.91
- Analyst Decision
- USGO Strong Buy
- ELTX Strong Buy
- Analyst Count
- USGO 1
- ELTX 2
- Target Price
- USGO $26.50
- ELTX $9.50
- AVG Volume (30 Days)
- USGO 37.0K
- ELTX 49.0K
- Earning Date
- USGO 08-12-2025
- ELTX 08-12-2025
- Dividend Yield
- USGO N/A
- ELTX N/A
- EPS Growth
- USGO N/A
- ELTX N/A
- EPS
- USGO N/A
- ELTX N/A
- Revenue
- USGO N/A
- ELTX N/A
- Revenue This Year
- USGO N/A
- ELTX N/A
- Revenue Next Year
- USGO N/A
- ELTX N/A
- P/E Ratio
- USGO N/A
- ELTX N/A
- Revenue Growth
- USGO N/A
- ELTX N/A
- 52 Week Low
- USGO $5.00
- ELTX $3.35
- 52 Week High
- USGO $14.46
- ELTX $9.99
- Technical
- Relative Strength Index (RSI)
- USGO 39.64
- ELTX 59.19
- Support Level
- USGO $8.09
- ELTX $7.57
- Resistance Level
- USGO $8.78
- ELTX $8.09
- Average True Range (ATR)
- USGO 0.43
- ELTX 0.31
- MACD
- USGO -0.11
- ELTX -0.10
- Stochastic Oscillator
- USGO 27.15
- ELTX 53.03
About USGO U.S. GoldMining Inc. Common stock
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.